The Next Frontier in Parkinson Disease Care: Exploring Gene and Cell Therapies
Explore the latest advancements in cell and gene therapies for Parkinson disease, featuring cutting-edge treatments and clinical trial updates from top innovators in the field.
Cell and gene therapies are emerging as key players in the treatment of Parkinson disease (PD), offering innovative strategies to slow or stop disease progression by targeting genetic mutations, neurotrophic factors, and protein aggregation. Among the most promising therapies in development are PR001, a gene therapy aimed at patients with PD GBA1 mutations, and AB-1005, which leverages glial cell line-derived neurotrophic factor (GDNF) to support dopaminergic neuron regeneration. UB-312, an active immunotherapy targeting pathological α-synuclein, is also showing promising early results, while other therapies like bemdaneprocel and AAV-GAD explore stem cell- and gene-based approaches to restore brain function.